Drugs targeting mglur5 receptor offer ‘fragile’ hope for autism

  • Williams S
  • 37


    Mendeley users who have this article in their library.
  • 8


    Citations of this article.


A group of drugs that are already racing through clinical trials to treat fragile X syndrome, a rare inherited syndrome that causes both intellectual disability and autistic behaviors, may have even broader usage. Mounting evidence suggests that the drugs, which block a glutamate receptor in the brain called mGluR5, might also work in certain forms of autism that have no known cause.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Sarah C P Williams

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free